Advanced Search
Search
  
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire

Other News Releases in Biotechnology

ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries

Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category

American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor

Other News Releases in Personnel Announcements

New Tri Tax President and CEO Frank Montano Brings Years of Corporate Leadership to Booming Company

Kelaher Joins Duck Creek's Board of Directors

Richmond Fed Announces Officer Promotions

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Supplementary Medicine, Personnel Announcements

 

WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology

SHANGHAI, July 23 /PRNewswire-Asia/ - WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Dr. Chi-Chung Chan has been appointed as Vice President of Pharmacology. He will report directly to Dr. Shuhui Chen, Chief Scientific Officer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi, Dr. Chi-Chung Chan worked at Merck & Co. for 26 years in scientific positions of increasing responsibility. At Merck, he led pharmacology research efforts in inflammation and pain, allergic diseases, cardiovascular diseases, respiratory diseases and, most recently, diabetes and obesity. Dr. Chan obtained a Ph.D. in Pharmacology from the University of Ottawa and a B.S. degree in Biology from Chinese University of Hong Kong.

"I am pleased to welcome Chi-Chung on board as we continue to develop our drug discovery capabilities in pharmacology," said Dr. Ge Li, Chairman and Chief Executive Officer. "WuXi is committed to building a world-class scientific management team with extensive experience in a broad range of scientific disciplines to meet the needs of our customers."

    For more information, please contact:

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Stephanie Liu (for the media)
     Associate Director of Corporate Communications Department
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

     Web: http://www.wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.